DDX10: A Drug Target / Disease Biomarker (G1662)

Target Name: DDX10

NCBI ID: G1662

DDX10

DDX10: A Drug Target / Disease Biomarker

DDX10 is a drug target and a biomarker that is being studied for its potential role in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Developed by Doxorubicin (DXR), a biotech company that specializes in drug discovery and development, DDX10 is designed to selectively bind to DNA damage sites and cause DNA double-strand breaks, leading to the suppression of gene expression and the inhibition of cell growth.

As a drug target, DDX10 has the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, DDX10 has been shown to be effective in treating various types of cancer, including breast, ovarian, and colorectal cancer. In preclinical studies, it has been shown to inhibit the growth of cancer cells and cause them to undergo apoptosis, which is a natural form of cell death that can help eliminate cancer cells.

In addition to its potential use in cancer treatment, DDX10 has also been studied for its potential use in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms, including memory loss, confusion, and difficulty with daily tasks.

DDX10 has been shown to be effective in treating neurodegenerative diseases by inhibiting the production of toxic proteins that can cause the damage to brain cells. In preclinical studies, it has been shown to improve cognitive function in individuals with neurodegenerative diseases and to protect brain cells from the effects of these proteins.

Finally, DDX10 has also been studied for its potential use in treating autoimmune disorders, such as rheumatoid arthritis and lupus. These conditions are characterized by the immune system attacking the body's own tissues, leading to a range of symptoms, including joint pain, fatigue, and inflammation.

In preclinical studies, DDX10 has been shown to be effective in treating autoimmune disorders by inhibiting the production of immune cells that can cause inflammation. This has the potential to reduce the symptoms of autoimmune disorders and improve their overall quality of life.

In conclusion, DDX10 is a drug target and biomarker with a wide range of potential applications in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to selectively bind to DNA damage sites and cause DNA double-strand breaks makes it an attractive potential therapeutic agent for the treatment of these conditions. Further research is needed to fully understand the potential benefits and risks of DDX10, and to determine its safety and efficacy in clinical trials.

Protein Name: DEAD-box Helicase 10

Functions: Putative ATP-dependent RNA helicase

The "DDX10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets